Tevogen (TVGN) provided stockholders a detailed overview of its artificial intelligence initiative, Tevogen.AI, aimed at integrating advanced machine learning into its ExacTcell technology to enhance target identification and preclinical processes. Tevogen.AI currently has two proprietary technologies, PredicTcell and AdapTcell, both with patents pending. The company also highlighted strategic partnerships with Microsoft (MSFT), providing AI expertise and cloud computing infrastructure, and Databricks, supplying data engineering and analytics capabilities. Tevogen plans to expand its headquarters for the Tevogen.AI team.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen announces planned expansion of TVGN 489’s target population
- Tevogen CEO says business model addresses biopharma industry challenges
- Biotech Alert: Searches spiking for these stocks today
- Tevogen CEO to join dialogue on Paths to Liquidity
- Tevogen sees launch year oncology business revenue $1B